USRE40546E1
(en)
*
|
1996-05-01 |
2008-10-21 |
Scarista, Ltd. |
1,3-Propane diol esters and ethers and methods for their use in drug delivery
|
MY118354A
(en)
*
|
1995-05-01 |
2004-10-30 |
Scarista Ltd |
1,3-propane diol derivatives as bioactive compounds
|
EP0823897B1
(en)
*
|
1995-05-01 |
2004-07-28 |
Scarista Limited |
Nicotinic acid esters and pharmaceutical compositions containing them
|
US5795909A
(en)
*
|
1996-05-22 |
1998-08-18 |
Neuromedica, Inc. |
DHA-pharmaceutical agent conjugates of taxanes
|
US6576636B2
(en)
*
|
1996-05-22 |
2003-06-10 |
Protarga, Inc. |
Method of treating a liver disorder with fatty acid-antiviral agent conjugates
|
WO1997048391A2
(en)
*
|
1996-06-21 |
1997-12-24 |
Advanced Research And Technology Institute |
Methods and compositions comprising r-ibuprofen
|
CN1237162A
(zh)
*
|
1996-11-12 |
1999-12-01 |
美国家用产品公司 |
Cox-2的茚抑制剂
|
US5869524A
(en)
*
|
1996-11-12 |
1999-02-09 |
American Home Products Corporation |
Indene inhibitors of COX-2
|
WO1998027972A2
(en)
*
|
1996-12-23 |
1998-07-02 |
Texas A & M University |
Anti-amyloidogenic agents
|
US6117911A
(en)
|
1997-04-11 |
2000-09-12 |
Neorx Corporation |
Compounds and therapies for the prevention of vascular and non-vascular pathologies
|
JP2002502881A
(ja)
*
|
1998-02-13 |
2002-01-29 |
ニュートラマックス ラボラトリーズ,インコーポレイテッド |
結合組織を保護、治療、および修復するための薬剤および方法
|
US6579551B1
(en)
|
1998-05-21 |
2003-06-17 |
Beech-Nut Nutrition Corporation |
Baby-food compositions containing egg yolk and methods therefor
|
US7413759B2
(en)
*
|
1998-05-21 |
2008-08-19 |
Beech-Nut Nutrition Corporation |
Method of enhancing cognitive ability in infant fed DHA containing baby-food compositions
|
US7141266B2
(en)
*
|
1998-05-21 |
2006-11-28 |
Beech-Nut Nutrition Corporation |
Baby-food compositions enhancing visual acuity and methods therefor
|
US6149964A
(en)
*
|
1998-05-21 |
2000-11-21 |
Beech-Nut Nutrition Corporation |
Egg yolk-containing baby food compositions and methods therefor
|
US6572871B1
(en)
*
|
1999-01-06 |
2003-06-03 |
W. Edward Church |
Pain treatment method and apparatus using heating wrap and analgesic cream
|
US20040073258A1
(en)
*
|
1999-01-06 |
2004-04-15 |
Church W. Edward |
Body tissue and skin treatment method using pulsing heating pad and topical cream
|
GB9901809D0
(en)
*
|
1999-01-27 |
1999-03-17 |
Scarista Limited |
Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
|
US7235583B1
(en)
*
|
1999-03-09 |
2007-06-26 |
Luitpold Pharmaceuticals, Inc., |
Fatty acid-anticancer conjugates and uses thereof
|
US6426367B1
(en)
*
|
1999-09-09 |
2002-07-30 |
Efa Sciences Llc |
Methods for selectively occluding blood supplies to neoplasias
|
US20060004086A1
(en)
*
|
2000-04-13 |
2006-01-05 |
Mayo Foundation For Medical Education And Research |
Method of reducing Abeta42 and treating diseases
|
AU2001257022B2
(en)
*
|
2000-04-13 |
2005-02-03 |
Mayo Foundation For Medical Education And Research |
Abeta 42 lowering agents
|
WO2001093680A1
(en)
*
|
2000-06-02 |
2001-12-13 |
Medinox, Inc. |
Protected forms of a combination of pharmacologically active agents and uses therefor
|
US6306842B1
(en)
*
|
2000-06-02 |
2001-10-23 |
Medinox, Inc. |
Protected forms of a combination of pharmacologically active agents and uses therefor
|
WO2002009725A1
(en)
*
|
2000-08-02 |
2002-02-07 |
Pharmanutrients |
Methods and compositions for the prevention and treatment of inflamation, osteoarthritis, and other degenerative joint diseases
|
WO2002009691A1
(en)
|
2000-08-02 |
2002-02-07 |
Pharmanutrients |
Methods and compositions for the prevention and treatment of syndrome x
|
US6838451B1
(en)
|
2000-08-02 |
2005-01-04 |
Pharmanutrients |
Methods and compositions for the prevention and treatment of inflammation, osteoarthritis, and other degenerative joint diseases
|
US6927239B1
(en)
*
|
2000-08-02 |
2005-08-09 |
Pharmanutrients |
Methods and compositions for the attenuation and/or prevention of stress/catabolic responses
|
WO2002083151A2
(en)
*
|
2000-12-14 |
2002-10-24 |
Tufts University |
Compositions and methods for treating an arthritic condition
|
AU2002303164A1
(en)
*
|
2001-03-23 |
2002-10-08 |
Protarga, Inc. |
Fatty amine drug conjugates
|
JP4634694B2
(ja)
*
|
2001-03-23 |
2011-02-16 |
ルイトポルド・ファーマシューティカルズ・インコーポレーテッド |
脂肪アルコール薬物複合体
|
GB0111282D0
(en)
*
|
2001-05-09 |
2001-06-27 |
Laxdale Ltd |
Potentiation of therapeutic effects of fatty acids
|
JP3977162B2
(ja)
*
|
2002-06-21 |
2007-09-19 |
株式会社バンダイナムコゲームス |
キャラクタ情報管理装置、プログラム及び情報記憶媒体
|
WO2004071431A2
(en)
*
|
2003-02-05 |
2004-08-26 |
Myriad Genetics, Inc. |
Method and composition for treating neurodegenerative disorders
|
JP2007528857A
(ja)
*
|
2003-07-11 |
2007-10-18 |
ミリアド ジェネティクス, インコーポレイテッド |
アルツハイマー病の処置のための薬学的方法、投与レジメンおよび投薬形態
|
US20050154059A1
(en)
*
|
2004-01-13 |
2005-07-14 |
Cook Mark E. |
Method of treating type III hypersensitive reaction-related diseases and conditions by using conjugated linoleic acid
|
US20090155903A1
(en)
*
|
2004-03-19 |
2009-06-18 |
Myriad Genetics, Incorporated |
Pharmaceutical composition and method
|
WO2006001877A2
(en)
*
|
2004-04-13 |
2006-01-05 |
Myriad Genetics, Inc. |
Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
|
KR20070004036A
(ko)
*
|
2004-04-29 |
2007-01-05 |
키스톤 리테이닝 월 시스템스, 아이엔씨 |
벽, 옹벽 및 그 외 유사한 것을 위한 베니어
|
WO2006020850A2
(en)
*
|
2004-08-11 |
2006-02-23 |
Myriad Genetics, Inc. |
Pharmaceutical composition and method for treating neurodegenerative disorders
|
BRPI0514303A
(pt)
*
|
2004-08-11 |
2008-06-10 |
Myriad Genetics Inc |
composição farmacêutica e método para tratar distúrbios neurodegenerativos
|
WO2006020852A2
(en)
*
|
2004-08-11 |
2006-02-23 |
Myriad Genetics, Inc. |
Pharmaceutical composition and method for treating neurodegenerative disorders
|
BRPI0516803A
(pt)
*
|
2004-11-19 |
2008-09-23 |
Martek Biosciences Corp |
oxilipinas de ácidos graxos polinsaturados de cadeia longa e métodos de produção e uso dos mesmos
|
US7893106B2
(en)
*
|
2004-11-19 |
2011-02-22 |
Martek Biosciences, Corporation |
Oxylipins from stearidonic acid and γ-linolenic acid and methods of making and using the same
|
US20090318394A1
(en)
*
|
2004-11-19 |
2009-12-24 |
Julie Nauroth |
Long Chain Polyunsaturated Fatty Acids and Methods of Making and Using the Same
|
EP1909777A2
(en)
*
|
2005-07-22 |
2008-04-16 |
Myriad Genetics, Inc. |
High drug load formulations and dosage forms
|
EP1983977A4
(en)
*
|
2006-01-31 |
2011-11-30 |
Martek Biosciences Corp |
OXYLIPINES FROM STEARIDONIC ACID AND GAMMA-LINOLIC ACID AND METHOD FOR THE PRODUCTION AND USE THEREOF
|
WO2008006099A2
(en)
*
|
2006-07-07 |
2008-01-10 |
Myriad Genetics, Inc. |
Treatment of psychiatric disorders
|
WO2008103753A2
(en)
*
|
2007-02-20 |
2008-08-28 |
Martek Biosciences Corporation |
Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same
|
WO2008153722A1
(en)
*
|
2007-05-22 |
2008-12-18 |
The Board Of Regents Of The University Of Texas System |
Post-translational regulation of catalytic activities of cytochrome p450 46a1 and uses thereof
|
US20110027841A1
(en)
*
|
2007-12-21 |
2011-02-03 |
Martek Biosciences Corporation |
Method for preparation of oxylipins
|
MX2011000273A
(es)
|
2008-07-08 |
2011-05-23 |
Catabasis Pharmaceuticals Inc |
Salicilatos acetilados con acidos grasos y sus usos.
|
US9085527B2
(en)
*
|
2008-07-08 |
2015-07-21 |
Catabasis Pharmaceuticals, Inc. |
Fatty acid acylated salicylates and their uses
|
DK2334295T3
(en)
|
2008-09-02 |
2017-10-09 |
Amarin Pharmaceuticals Ie Ltd |
PHARMACEUTICAL COMPOSITION COMPREHENSIVE EICOSAPENTAIC ACID AND NICOTIC ACID AND PROCEDURES FOR USING SAME
|
US20110229565A1
(en)
*
|
2008-09-17 |
2011-09-22 |
Karp Jeffrey M |
Drug Delivery Composition Comprising a Self-Assembled Gelator
|
BRPI0919979A2
(pt)
|
2008-10-29 |
2015-12-15 |
Wyeth Llc |
formulações de moléculas de ligação de antígeno de domínio único
|
US10118962B2
(en)
|
2008-10-29 |
2018-11-06 |
Ablynx N.V. |
Methods for purification of single domain antigen binding molecules
|
ES2768091T3
(es)
|
2009-02-10 |
2020-06-19 |
Amarin Pharmaceuticals Ie Ltd |
Uso del éster etílico del ácido eicosapentaenoico para tratar la hipertrigliceridemia
|
NZ627238A
(en)
|
2009-04-29 |
2016-02-26 |
Amarin Pharmaceuticals Ie Ltd |
Stable pharmaceutical composition comprising ethyl eicosapentaenoate
|
MY198422A
(en)
|
2009-04-29 |
2023-08-29 |
Amarin Pharmaceuticals Ie Ltd |
Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
|
MY172372A
(en)
|
2009-06-15 |
2019-11-21 |
Amarin Pharmaceuticals Ie Ltd |
Compositions and methods for lowering triglycerides
|
SG10201500431SA
(en)
|
2009-09-01 |
2015-03-30 |
Catabasis Pharmaceuticals Inc |
Fatty acid niacin conjugates and their uses
|
USRE46608E1
(en)
|
2009-09-01 |
2017-11-14 |
Catabasis Pharmaceuticals, Inc. |
Fatty acid niacin conjugates and their uses
|
US20110064813A1
(en)
*
|
2009-09-16 |
2011-03-17 |
Charles Vaughn |
Use of salsalate with or without caffeine and with or without omega 3, and other pharmaceutical compounds in a distinctively unique nano-particulate capsule and tablet
|
RU2758369C2
(ru)
|
2009-09-23 |
2021-10-28 |
Амарин Фармасьютикалз Айрлэнд Лимитед |
Фармацевтическая композиция, включающая омега-3 жирную кислоту и гидроксипроизводное статина, и способы ее применения
|
US8715699B2
(en)
*
|
2009-12-31 |
2014-05-06 |
Kempharm, Inc. |
Amino acid conjugates of quetiapine, process for making and using the same
|
JP2013517322A
(ja)
*
|
2010-01-20 |
2013-05-16 |
プロノヴァ・バイオファーマ・ノルゲ・アーエス |
サリチレート脂肪酸誘導体
|
KR20130026428A
(ko)
*
|
2010-03-04 |
2013-03-13 |
아마린 파마, 인크. |
심혈관 질환을 치료 및/또는 예방하기 위한 조성물 및 방법
|
WO2011109681A1
(en)
*
|
2010-03-05 |
2011-09-09 |
Catabasis Pharmaceuticals, Inc. |
Fatty acid cox inhibitor derivatives and their uses
|
PL2544536T3
(pl)
*
|
2010-03-11 |
2019-05-31 |
Kempharm Inc |
Koniugaty kwasów tłuszczowych z kwetiapiną, sposób ich wytwarzania i stosowania
|
WO2011116312A1
(en)
*
|
2010-03-19 |
2011-09-22 |
Catabasis Pharmaceuticals, Inc. |
Fatty acid macrolide derivatives and their uses
|
EP2593476A2
(en)
*
|
2010-07-16 |
2013-05-22 |
Ablynx N.V. |
Modified single domain antigen binding molecules and uses thereof
|
WO2012040623A2
(en)
|
2010-09-24 |
2012-03-29 |
The Brigham And Women's Hospital, Inc. |
Nanostructured gels capable of controlled release of encapsulated agents
|
US20140127289A1
(en)
|
2010-11-29 |
2014-05-08 |
Armarin Pharmaceuticals Ireland Limited |
Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
|
US11712429B2
(en)
|
2010-11-29 |
2023-08-01 |
Amarin Pharmaceuticals Ireland Limited |
Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
|
CN103384521A
(zh)
*
|
2010-12-21 |
2013-11-06 |
雀巢产品技术援助有限公司 |
用于预防和治疗骨关节炎的方法和组合物
|
US9730884B2
(en)
*
|
2011-09-29 |
2017-08-15 |
Plx Opco Inc. |
pH dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same
|
US11291643B2
(en)
|
2011-11-07 |
2022-04-05 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating hypertriglyceridemia
|
EP2775837A4
(en)
|
2011-11-07 |
2015-10-28 |
Amarin Pharmaceuticals Ie Ltd |
METHODS OF TREATING HYPERTRIGLYCERIDEMIA
|
AU2013207368A1
(en)
|
2012-01-06 |
2014-07-24 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering levels of high-sensitivity (hs-CRP) in a subject
|
BR112014032905B1
(pt)
|
2012-06-29 |
2022-02-22 |
Amarin Pharmaceuticals Ireland Limited |
Uso de éster etílico do ácido eicosapentaenóico para redução do risco de morte cardiovascular, revascularização coronária e/ou angina instável em um indivíduo em terapia com estatina
|
US20150265566A1
(en)
|
2012-11-06 |
2015-09-24 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy
|
US20140187633A1
(en)
|
2012-12-31 |
2014-07-03 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
|
US9814733B2
(en)
|
2012-12-31 |
2017-11-14 |
A,arin Pharmaceuticals Ireland Limited |
Compositions comprising EPA and obeticholic acid and methods of use thereof
|
US9452151B2
(en)
|
2013-02-06 |
2016-09-27 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing apolipoprotein C-III
|
US9624492B2
(en)
|
2013-02-13 |
2017-04-18 |
Amarin Pharmaceuticals Ireland Limited |
Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
|
US9662307B2
(en)
|
2013-02-19 |
2017-05-30 |
The Regents Of The University Of Colorado |
Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
|
US9283201B2
(en)
|
2013-03-14 |
2016-03-15 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for treating or preventing obesity in a subject in need thereof
|
US20140271841A1
(en)
|
2013-03-15 |
2014-09-18 |
Amarin Pharmaceuticals Ireland Limited |
Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
|
US10966968B2
(en)
|
2013-06-06 |
2021-04-06 |
Amarin Pharmaceuticals Ireland Limited |
Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
|
US20150065572A1
(en)
|
2013-09-04 |
2015-03-05 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating or preventing prostate cancer
|
US9585859B2
(en)
|
2013-10-10 |
2017-03-07 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
|
KR102530119B1
(ko)
|
2013-12-24 |
2023-05-08 |
버지니아 커먼웰스 유니버시티 |
산소첨가된 콜레스테롤 술페이트 (ocs) 의 용도
|
US10561631B2
(en)
|
2014-06-11 |
2020-02-18 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing RLP-C
|
US10172818B2
(en)
|
2014-06-16 |
2019-01-08 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
|
US9603869B2
(en)
|
2015-05-22 |
2017-03-28 |
University Of South Florida |
Lithium co-crystals and an additional neuropsychiatric agent for treatment of neuropsychiatric disorders
|
AU2016335846B2
(en)
|
2015-10-08 |
2019-04-04 |
The Brigham And Women's Hospital, Inc. |
Stabilized assembled nanostructures for delivery of encapsulated agents
|
US10406130B2
(en)
|
2016-03-15 |
2019-09-10 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
|
CN115837006A
(zh)
|
2016-05-06 |
2023-03-24 |
布里格姆及妇女医院股份有限公司 |
用于向软骨中受控递送被囊封的药剂的二元自组装凝胶
|
US11020410B2
(en)
|
2017-02-03 |
2021-06-01 |
The Brigham And Women's Hospital, Inc. |
Self-assembled gels formed with anti-retroviral drugs, prodrugs thereof, and pharmaceutical uses thereof
|
JP7211974B2
(ja)
|
2017-05-08 |
2023-01-24 |
アリヴィオ セラピューティクス, インコーポレイテッド |
増大した薬剤負荷および接着のためのナノ構造化ゲルの製剤
|
WO2018213663A1
(en)
|
2017-05-19 |
2018-11-22 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides in a subject having reduced kidney function
|
US11058661B2
(en)
|
2018-03-02 |
2021-07-13 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
|
AU2019349563B2
(en)
|
2018-09-24 |
2023-06-08 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing the risk of cardiovascular events in a subject
|
JP2023518822A
(ja)
|
2020-03-26 |
2023-05-08 |
ピーエルエックス オプコ インコーポレイテッド |
pH依存的再構築が可能な医薬キャリア、その製造方法及び使用方法
|
AU2022263358A1
(en)
|
2021-04-21 |
2023-11-30 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing the risk of heart failure
|